- recruitingTherapeutic exploratory (Phase II)
An open-label, roll-over study with rilpivirine in combination with a background regimen containing other antiretrovirals (ARVs) in human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies.
This study is for adults with HIV-1 who previously took part in childhood clinical trials for an antiviral medicine called rilpivirine. It allows participants to carry on receiving rilpivirine alongside their other HIV treatments, helping doctors see how well the medicine works and how safe it is over time.
Italy - recruitingPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1
This study is testing new medicines for people recently diagnosed with HIV-1. It compares a weekly pill combining GS-1720 and GS-4182 against a daily pill called Biktarvy. The main goal is to see which treatment best controls the virus.
Romania · Spain · Poland - recruitingHuman Pharmacology (Phase I)- Other
MK-8507 Extended Multiple Dose Study
This study is looking at a new medicine called MK-8507 for HIV-1 infection. It's an early-stage study to see how the medicine works in the body and if it's safe when taken multiple times. It involves adults aged 18 and over.
Belgium - recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily
This study is testing a new weekly pill for adults with HIV-1, who are already doing well on their current daily medication. It aims to see how safe and effective a switch to the new treatment is.
France - recruitingTherapeutic confirmatory (Phase III)
A Phase IIIb, multi-center, non-randomized, parallel-group, open-label, hybrid type I study evaluating the efficacy, safety, implementation effectiveness, and patient-reported outcomes of oral dolutegravir/lamivudine once-daily as a first-line regimen followed by participant-determined optional switch to long-acting intramuscular cabotegravir plus rilpivirine every two months for the maintenance of virologic suppression in antiretroviral therapy naive adults living with HIV-1.
This study looks at new ways to treat HIV-1 in adults who haven't had treatment before. It starts with daily tablets, and then some people can switch to injections every two months. The aim is to see how well these treatments work, if they're safe, and how they affect patients' lives.
Italy · France · Spain - recruitingTherapeutic use (Phase IV)
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV
This study looks at a new one-pill treatment for HIV, called Biktarvy, after people stop a different injectable HIV medicine. Researchers want to see if Biktarvy is safe, how well the body uses it, and if it keeps HIV under control for adults.
France - active not recruitingPHASE2, PHASE3
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
This study is testing a new medicine called lenacapavir for people with HIV-1 who haven't responded well to other treatments. It aims to see if adding lenacapavir to their current treatment helps reduce the amount of virus in their body.
United States · Canada · Dominican Republic - active not recruitingPHASE3
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
This study is an ongoing look at a two-drug tablet called MK-8591A for people with HIV-1. It's for those already taking this medicine in previous studies to see how safe and effective it is over a longer time.
United States · Australia · Canada - active not recruitingPHASE3
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
This study is testing a new combination medicine, DOR/ISL, for people newly diagnosed with HIV-1 who haven't started treatment yet. It compares this new medicine to an existing treatment to see if it's as good at reducing the amount of HIV in the body.
United States · Argentina · Canada - active not recruitingPHASE3
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
This study looks at a new two-in-one medicine, Doravirine/Islatravir (DOR/ISL), for people with HIV-1 whose virus is already under control. It wants to see if switching to this new medicine is safe and works as well as their current treatment.
United States · Australia · Canada - active not recruitingPHASE3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
This study looks at switching HIV-1 positive people who are stable on Biktarvy to a new combination treatment called bictegravir/lenacapavir. We want to see if this new treatment works just as well and is safe.
United States · Argentina · Australia - active not recruitingPHASE3
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
This study is looking at a new once-weekly tablet called islatravir/lenacapavir (ISL/LEN) for people living with HIV-1. It compares switching to this new tablet with continuing their current daily HIV treatment to see if it's safe and works well.
United States · Argentina · Australia - active not recruitingPHASE3
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
This study is looking at a new once-a-week tablet for people with HIV. It compares switching to this new tablet (islatravir/lenacapavir) with continuing their usual daily treatment (bictegravir/emtricitabine/tenofovir alafenamide). It aims to see if the new weekly tablet is safe and works just as well for people whose HIV is already well controlled.
United States · Argentina · Australia - not yet recruitingPHASE4
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
This study looks at switching HIV patients already on opioid addiction treatment to a new HIV medicine called Dovato. We want to see if Dovato keeps their HIV under control and if it's safe for them.
Canada - active not recruiting
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
The MISTRAL study investigates how gut bacteria affect people living with HIV, especially those over 50. It aims to find ways to improve health, reduce complications like inflammation, and make treatments and vaccines work better by understanding the gut microbiome.
Belgium · Croatia · Czechia - authorisedTherapeutic exploratory (Phase II)
Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.
This study is testing a drug called dasatinib for people with HIV. It aims to see if dasatinib can reduce hidden HIV, calm inflammation, and improve immune system health in those already taking long-term HIV medicines. Researchers are also looking at its safety.
Spain - recruitingPHASE3
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
This study looks at a new two-pill HIV treatment combining doravirine and dolutegravir. It aims to see if switching to this simplified treatment is as good and safe as current three-pill treatments for people living with HIV who have their virus under control.
United Kingdom - recruiting
HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
This study looks at how HIV, the virus that causes AIDS, changes over time, especially when new treatments are introduced. Researchers want to understand if the virus becomes resistant to medicines and how this impacts people in Eastern Europe and Russia.
Germany · Italy · Poland - active not recruitingPHASE2
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
This study is testing new medicines (teropavimab, zinlirvimab, and lenacapavir) for people with HIV-1 whose virus is already under control. It compares these new drugs to their usual medication to see if they are safe and work well.
United States · Australia · Canada - authorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.
France · Germany · Poland - active not recruitingPHASE3
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
This study looks at a new two-drug HIV treatment, Doravirine/Islatravir (DOR/ISL), for people living with HIV-1 who are currently doing well on another common treatment, Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF). Researchers want to see if switching to the new treatment is as effective and safe.
United States · Australia · Chile - active not recruitingPHASE2, PHASE3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
This study is looking for people with HIV-1 who are currently on a complex treatment plan. It compares a new two-drug combination, bictegravir and lenacapavir, with their current treatment to see if it's a simpler and effective option.
United States · Argentina · Australia